NCT04585035 - Study to Evaluate D-1553 in Subjects With Solid Tumors | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

October 2, 2020

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2025

Conditions

Solid Tumor, AdultNSCLCCRC

Interventions

DRUG

D-1553

D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

DRUG

D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other

Standard treatment of solid tumor, NSCLC or CRC

Trial Locations (25)

333

Research Site, Taoyuan

704

Research Site, Tainan City

2148

Research Site, Blacktown

2217

Research Site, Kogarah

2298

Research Site, Waratah

2640

Research Site, East Albury

3065

Research Site, Fitzroy

3144

Research Site, Malvern

3199

Research Site, Frankston

5011

Research Site, Woodville South

6009

Research Site, Nedlands

10002

Research Site, Taipei

11217

Research Site, Taipei

11432

Research Site, New York

40202

Research Site, Louisville

48202

Research Site, Detroit

92868

Research Site, Orange

93720

Research Site, Fresno

94158

Research Site, San Francisco

97213

Research Site, Portland

602-715

Research Site, Seogu

463-707

Research Site, Seongnam-si

06591

Research Site, Seoul

138-736

Research Site, Seoul

152-703

Research Site, Seoul